A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 5, 2010, Pages 862-873

  Pacilio, Massimiliano ^a   Betti, Margherita ^b   Cicone, Francesco ^b   Del Mastro, Carolina ^b   Montani, Livia ^c   Chiacchiararelli, Laura ^c   Monaco, Alessia ^a   Santini, Enrico ^a   Scopinaro, Francesco ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BED; Dosimetry; Lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN;

ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLICULAR LYMPHOMA; HEART; HUMAN; KIDNEY PARENCHYMA; LARGE CELL LYMPHOMA; LIVER; LIVER TOXICITY; LUNG PARENCHYMA; LUNG TOXICITY; LYMPH NODE; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MALE; NEPHROTOXICITY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGIC EFFECTIVENESS; SPLEEN; TESTIS; TISSUE DISTRIBUTION;

AGED; ANTIBODIES, MONOCLONAL; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; UNCERTAINTY;

EID: 77952096104     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1333-4     Document Type: Article

References (45)

1. GA Wiseman E Kornmehl B Leigh WD Erwin DA Podoloff S Spies, et al. 2003 Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials J Nucl Med 44 465 474 1:CAS:528: DC%2BD3sXislKnurw%3D 12621016 (Pubitemid 39586026)
2. GA Wiseman CA White RB Sparks, et al. 2001 Biodistribution and dosimetry results from phase III prospectively randomized, controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Crit Rev Oncol Hematol 39 181 194 10.1016/S1040-8428(01)00107-X 1:STN:280:DC%2BD38%2Fit1ahsA%3D%3D 11418315 (Pubitemid 32564871)
3. GA Wiseman CA White M Stabin, et al. 2000 Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Eur J Nucl Med 27 766 777 10.1007/s002590000276 1:CAS:528:DC%2BD3cXktVOjsL8%3D 10952488 (Pubitemid 30456759)
4. M Cremonesi M Ferrari CM Grana A Vanazzi M Stabin M Bartolomei, et al. 2007 High-dose radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: comparative dosimetric study for tailored treatment J Nucl Med 48 1871 1879 10.2967/jnumed.107.044016 17978355 (Pubitemid 350103424)
5. L Devizzi A Guidetti C Tarella M Magni P Matteucci E Seregni, et al. 2008 High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation J Clin Oncol 26 5175 5182 10.1200/JCO.2008.16.8294 1:CAS:528:DC%2BD1cXhsVyqsrnF 18854569
6. C Chiesa F Botta A Coliva M Maccauro L Devizzi A Guidetti, et al. 2008 Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin) Eur J Nucl Med Mol Imaging 36 1745 1757 10.1007/s00259-009- 1141-x
7. S Baechler RF Hobbs AR Prideaux M Recordon A Bischof-Delaloye G Sgouros 2008 Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan Cancer Biother Radiopharm 23 633 639 10.1089/cbr.2008.0506 1:CAS:528:DC%2BD1cXhtlKis7nP 18999935
8. R Barone F Borson-Chazot R Valkema, et al. 2005 Patient specific dosimetry in predicting renal toxicity with 90YDOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J Nucl Med 46 99S 106S 1:CAS:528:DC%2BD2MXhsVeksLc%3D 15653658 (Pubitemid 47619025)
9. M Pacilio M Betti F Cicone, et al. 2008 Improvement of 90Y-Zevalin dosimetry by indirect Monte Carlo calculation of tumor biologically effective doses and their correlation with clinical outcomes. Preliminary results Eur J Nucl Med Mol Imaging 35 Suppl 2 S235 Abstract
10. RW Howell S Murty Goddu DV Rao 1994 Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides J Nucl Med 35 1861 1869 1:CAS:528:DyaK2MXis1SmsL8%3D 7965170
11. RG Dale 1985 The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 515 528 10.1259/0007-1285-58-690-515 1:STN:280:DyaL28%2Flt1arsw%3D%3D 4063711
12. WT Millar 1991 Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy Br J Radiol 64 242 251 10.1259/0007-1285-64-759-242 1:STN:280:DyaK3M3hsFersQ%3D%3D 2021798
13. DJ Brenner LR Hlatky PJ Hahnfeldt Y Huang RK Sachs 1998 The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships Radiat Res 150 83 91 10.2307/3579648 1:CAS:528:DyaK1cXktF2htrw%3D 9650605 (Pubitemid 28285628)
14. S Baechler RF Hobbs AR Prideaux, et al. 2008 Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry Med Phys 35 1123 1133 10.1118/1.2836421 18404947 (Pubitemid 351322658)
15. B Emami J Lyman A Brown L Coia M Goitein JE Munzenrider, et al. 1991 Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 109 122 1:STN:280:DyaK3M3js1CktA%3D%3D 2032882
16. KB Rachel PM Evans GD Flux 2004 Application of the linear-quadratic model to combined modality radiotherapy Int J Radiat Oncol Biol Phys 59 228 241 (Pubitemid 38501528)
17. RK Bodey GD Flux PM Evans 2003 Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose Cancer Biother Radiopharm 18 89 97 10.1089/108497803321269368 1:STN:280:DC%2BD3s7ltFGjsg%3D%3D 12667312
18. MG Stabin 2008 Uncertainties in internal dose calculations for radiopharmaceuticals J Nucl Med 49 853 860 10.2967/jnumed.107.048132 18413398 (Pubitemid 351717553)
19. Cicone F, Baldini R, Cox MC, Russo E, Torelli F, Tofani A, et al. Radioimmunotherapy of heavily pre-treated, non-Hodgkin lymphoma patients: efficacy and safety in a routine setting. Anticancer Res 2009;29:4771-4778.
20. J Tennvall M Fischer A Bischof Delaloye E Bombardieri L Bodei F Giammarile, et al. 2007 EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) Eur J Nucl Med Mol Imaging 34 616 622 10.1007/s00259-007-0372-y 17323056 (Pubitemid 46427010)
21. ME Juweid S Stroobants OS Hoekstra Fm Mottaghy M Dietlein A Guermazi Imaging Subcommittee of International Harmonization Project in Lymphoma, et al. 2007 Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 571 578 10.1200/JCO.2006.08.2305 17242397 (Pubitemid 350002965)
22. YE Erdi BW Wessels MH Loew AK Erdi 1995 Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy Cancer Res 55 5823s 5826s 1:CAS:528:DyaK2MXps12htbY%3D 7493353
23. MG Stabin RB Sparks E Crowe 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 1023 1027 15937315 (Pubitemid 43733519)
24. JA Siegel SR Thomas JB Stubbs, et al. 1999 MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates J Nucl Med 40 37S 61S 1:CAS:528:DyaK1MXivVGlsrg%3D 10025848
25. WC Buijs JA Siegel OC Boerman FH Corstens 1998 Absolute organ activity estimate by five different methods of background correction J Nucl Med 39 2167 2172 1:STN:280:DyaK1M%2FotlSmsA%3D%3D 9867163
26. G Sgouros 1993 Bone marrow dosimetry for radioimmunotherapy: theoretical considerations J Nucl Med 34 689 694 1:STN:280:DyaK3s3gtl2nuw%3D%3D 8455089 (Pubitemid 23115673)
27. BW Wessels WE Bolch LG Bouchet HD Breitz GL DeNardo RF Meredith, et al. 2004 Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison J Nucl Med 45 1725 1733 15471841
28. C Chiesa F Botta E Di Betta A Coliva M Maccauro G Aliberti, et al. 2007 Dosimetry in myeloablative 90Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results Cancer Biother Radiopharm 22 113 120 10.1089/cbr.2007.302 1:CAS:528:DC%2BD2sXksF2rsbk%3D 17627419 (Pubitemid 46697372)
29. WE Bolch LG Bouchet JS Robertson BW Wessels JA Siegel RW Howell, et al. 1999 MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions - radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee J Nucl Med 40 11S 36S 1:CAS:528:DyaK1MXos1aitQ%3D%3D 9935083
30. M Pacilio N Lanconelli S Lo Meo M Betti L Montani LA Torres Aroche, et al. 2009 Differences among Monte Carlo codes in the calculations of voxel S-values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations Med Phys 36 1543 1552 10.1118/1.3103401 1:CAS:528:DC%2BD1MXlsValt74%3D 19544770
31. RF Hobbs G Sgouros 2009 Calculation of the biological effective dose for piecewise defined dose-rate fits Med Phys 36 904 907 10.1118/1.3070587 19378750
32. T Alati M Van Cleeff SC Strom RL Jirtle 1988 Radiation sensitivity of adult human parenchymal hepatocytes Radiat Res 1 152 160 10.2307/3577063
33. S Schultz-Hector M Sund HD Thames 1992 Fractionation response and repair kinetics of radiation-induced heart failure in the rat Radiother Oncol 1 33 40 10.1016/0167-8140(92)90303-C
34. E van Rongen EL Travis HD Thames Jr 1995 Repair rate in mouse lung after clinically relevant radiation doses per fraction Radiat Res 1 74 78 10.2307/3579092
35. E van Rongen HD Thames Jr EL Travis 1993 Recovery from radiation damage in mouse lung: interpretation in terms of two rates of repair Radiat Res 2 225 233 10.2307/3578360 (Pubitemid 23086717)
36. HD Thames KK Ang FA Stewart E van Der Schuren 1988 Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol 54 13 19 10.1080/09553008814551461 1:STN:280:DyaL1c3osF2gtw%3D%3D 2899610
37. Halperin EC, Perez Carlos AP, Brady LW. Principles and practice of radiation oncology, 5th edn. Philadelphia: Lippincott Williams & Wilkins, Philadelphia; 2008.
38. RG Dale 1996 Dose-rate effects in targeted radiotherapy Phys Med Biol 41 1871 1884 10.1088/0031-9155/41/10/001 1:STN:280:DyaK2s%2FmvFaitw%3D%3D 8912367 (Pubitemid 26333627)
39. GA Wiseman BR Leigh WL Dunn MG Stabin CA White 2003 Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy Biother Radiopharm 18 253 258 10.1089/108497803765036436 1:CAS:528:DC%2BD3sXjsFejtb4%3D
40. K Assié A Dieudonné I Gardin I Buvat H Tilly P Vera 2008 Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma Cancer Biother Radiopharm 23 53 65 10.1089/cbr.2007.372 18298329 (Pubitemid 351304220)
41. B He RL Wahl G Sgouros Y Du H Jacene WR Kasecamp, et al. 2009 Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning - patient studies Med Phys 36 1595 1601 10.1118/1.3100265 19544775 (Pubitemid 351479144)
42. B He Y Du WP Segars RL Wahl G Sgouros H Jacene, et al. 2009 Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake Med Phys 36 612 619 10.1118/1.3063156 19292001
43. MC Hernandez SJ Knox 2004 Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma Int J Radiation Oncol Biol Phys 59 1274 1287 1:CAS:528:DC%2BD2cXmtVWhsLg%3D
44. RL Haas P Poortmans D de Jong BM Aleman LG Dewit M Verheij, et al. 2003 High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas J Clin Oncol 21 2474 2480 10.1200/JCO.2003.09.542 1:STN:280:DC%2BD3szgtFOrug%3D%3D 12829665 (Pubitemid 46606327)
45. RL Haas 2009 Low dose radiotherapy in indolent lymphomas, enough is enough Hematol Oncol 27 71 81 10.1002/hon.882 1:CAS:528:DC%2BD1MXos1Whs74%3D 19266491